The Hidden Story of Heterogeneous B-raf V600E Mutation Quantitative Protein Expression in Metastatic Melanoma—Association with Clinical Outcome and Tumor Phenotypes
Open accessPublished version of a preprint
The DOI matches its Crossref record; 63 of the 64 references it cites were found in a registry or an index.
Abstract
In comparison to other human cancer types, malignant melanoma exhibits the greatest amount of heterogeneity. After DNA-based detection of the BRAF V600E mutation in melanoma patients, targeted inhibitor treatment is the current recommendation. This approach, however, does not take the abundance of the therapeutic target, i.e., the B-raf V600E protein, into consideration. As shown by immunohistochemistry, the protein expression profiles of metastatic melanomas clearly reveal the existence of inter- and intra-tumor variability. Nevertheless, the technique is only semi-quantitative. To quantitate the mutant protein there is a fundamental need for more precise techniques that are aimed at defining the currently non-existent link between the levels of the target protein and subsequent drug efficacy. Using cutting-edge mass spectrometry combined with DNA and mRNA sequencing, the mutated B-raf protein within metastatic tumors was quantitated for the first time. B-raf V600E protein analysis revealed a subjacent layer of heterogeneity for mutation-positive metastatic melanomas. These were characterized into two distinct groups with different tumor morphologies, protein profiles and patient clinical outcomes. This study provides evidence that a higher level of expression in the mutated protein is associated with a more aggressive tumor progression. Our study design, comprised of surgical isolation of tumors, histopathological characterization, tissue biobanking, and protein analysis, may enable the eventual delineation of patient responders/non-responders and subsequent therapy for malignant melanoma.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures






Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Of note, melanoma tumour genomic BRAF driver mutations match corresponding protein sequences97, illustrating that proteomic landscapes add value to genomic data, when considered with patient tumour histopathology and clinical metadata98.”
From A high-stringency blueprint of the human proteome (2020) · cites this paper as [97]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The Perseus computational platform for comprehensive analysis of (prote)omics data
Tyanova, S., Temu, T., Sinitcyn, P., Carlson, A., Hein, M. Y., Geiger, T., Mann, M., & Cox, J. (2016) · Nature Methods · doi:10.1038/nmeth.3901 · Cited by 8,803
Genomic classification of cutaneous melanoma
Akbani, R., Akdemir, K. C., Aksoy, B. A., Albert, M., Ally, A., Amin, S. B., Arachchi, H., Arora, A., Auman, J. T., Ayala, B., et al. (2015) · Cell · doi:10.1016/j.cell.2015.05.044 · Cited by 3,151
An immunogenic personal neoantigen vaccine for patients with melanoma
Ott, P. A., Hu, Z., Keskin, D. B., Shukla, S. A., Sun, J., Bozym, D. J., Zhang, W., Luoma, A., Giobbie-Hurder, A., Peter, L., et al. (2017) · Nature · doi:10.1038/nature22991 · Cited by 2,936
Mechanism of Activation of the RAF-ERK Signaling Pathway by Oncogenic Mutations of B-RAF
Wan, P. T. C., Garnett, M. J., Roe, S. M., Lee, S., Niculescu-Duvaz, D., Good, V. M., Project, C. G., Jones, C. M., Marshall, C. J., Springer, C. J., et al. (2004) · Cell · doi:10.1016/s0092-8674(04)00215-6 · Cited by 2,808
Improved Overall Survival in Melanoma with Combined Dabrafenib and Trametinib
Robert, C., Karaszewska, B., Schachter, J., Rutkowski, P., Mackiewicz, A., Stroiakovski, D., Lichinitser, M., Dummer, R., Grange, F., Mortier, L., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1412690 · Cited by 2,701
Balch, C. M., Soong, S.-J., Gershenwald, J. E., Thompson, J. F., Reintgen, D. S., Cascinelli, N., Urist, M., McMasters, K. M., Ross, M. I., Kirkwood, J. M., et al. (2001) · Journal of Clinical Oncology · doi:10.1200/jco.2001.19.16.3622 · Cited by 2,388
Gershenwald, J. E., Scolyer, R. A., Hess, K. R., Sondak, V. K., Long, G. V., Ross, M. I., Lazar, A. J., Faries, M. B., Kirkwood, J. M., McArthur, G. A., et al. (2017) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21409 · Cited by 2,283
BRAFE600-associated senescence-like cell cycle arrest of human naevi
Michaloglou, C., Vredeveld, L. C. W., Soengas, M. S., Denoyelle, C., Kuilman, T., van der Horst, C. M. A. M., Majoor, D. M., Shay, J. W., Mooi, W. J., & Peeper, D. S. (2005) · Nature · doi:10.1038/nature03890 · Cited by 2,160 · cited 1×
“Interestingly, a previous study has shown that B-raf V600E-expressing melanocytes display classical hallmarks of senescence, thus suggesting that oncogene-induced senescence represents a genuine protective physiological process [51].”
BackgroundCombined BRAF and MEK Inhibition versus BRAF Inhibition Alone in Melanoma
Long, G. V., Stroyakovskiy, D., Gogas, H., Levchenko, E., de Braud, F., Larkin, J., Garbe, C., Jouary, T., Hauschild, A., Grob, J. J., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1406037 · Cited by 1,899
Five-year outcomes with dabrafenib plus trametinib in metastatic melanoma
Robert, C., Grob, J. J., Stroyakovskiy, D., Karaszewska, B., Hauschild, A., Levchenko, E., Chiarion Sileni, V., Schachter, J., Garbe, C., Bondarenko, I., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1904059 · Cited by 1,389
How many human proteoforms are there?
Aebersold, R., Agar, J. N., Amster, I. J., Baker, M. S., Bertozzi, C. R., Boja, E. S., Costello, C. E., Cravatt, B. F., Fenselau, C., Garcia, B. A., et al. (2018) · Nature Chemical Biology · doi:10.1038/nchembio.2576 · Cited by 907
Ribosome biogenesis in cancer: new players and therapeutic avenues
Pelletier, J., Thomas, G., & Volarević, S. (2018) · Nature Reviews Cancer · doi:10.1038/nrc.2017.104 · Cited by 812
Proteogenomic Analysis of Human Colon Cancer Reveals New Therapeutic Opportunities
Vasaikar, S., Huang, C., Wang, X., Petyuk, V. A., Savage, S. R., Wen, B., Dou, Y., Zhang, Y., Shi, Z., Arshad, O. A., et al. (2019) · Cell · doi:10.1016/j.cell.2019.03.030 · Cited by 799
Self-citationResolving genetic heterogeneity in cancer
Turajlic, S., Sottoriva, A., Graham, T., & Swanton, C. (2019) · Nature Reviews Genetics · doi:10.1038/s41576-019-0114-6 · Cited by 653
Excessive Cell Growth Causes Cytoplasm Dilution And Contributes to Senescence
Neurohr, G. E., Terry, R. L., Lengefeld, J., Bonney, M., Brittingham, G. P., Moretto, F., Miettinen, T. P., Vaites, L. P., Soares, L. M., Paulo, J. A., et al. (2019) · Cell · doi:10.1016/j.cell.2019.01.018 · Cited by 518
BRAF/NRAS Mutation Frequencies Among Primary Tumors and Metastases in Patients With Melanoma
Colombino, M., Capone, M., Lissia, A., Cossu, A., Rubino, C., De Giorgi, V., Massi, D., Fonsatti, E., Staibano, S., Nappi, O., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.41.2452 · Cited by 471
Cheng, L., Lopez-Beltran, A., Massari, F., MacLennan, G. T., & Montironi, R. (2018) · Modern Pathology · doi:10.1038/modpathol.2017.104 · Cited by 407
Intratumor and Intertumor Heterogeneity in Melanoma
Grzywa, T. M., Paskal, W., & Włodarski, P. K. (2017) · Translational Oncology · doi:10.1016/j.tranon.2017.09.007 · Cited by 299
Long, G. V., Wilmott, J. S., Capper, D., Preusser, M., Zhang, Y. E., Thompson, J. F., Kefford, R. F., von Deimling, A., & Scolyer, R. A. (2013) · American Journal of Surgical Pathology · doi:10.1097/pas.0b013e31826485c0 · Cited by 298
Intra- and Inter-Tumor Heterogeneity of BRAFV600EMutations in Primary and Metastatic Melanoma
Yancovitz, M., Litterman, A., Yoon, J., Ng, E., Shapiro, R. L., Berman, R. S., Pavlick, A. C., Darvishian, F., Christos, P., Mazumdar, M., et al. (2012) · PLoS ONE · doi:10.1371/journal.pone.0029336 · Cited by 283
Thomas, N. E., Edmiston, S. N., Alexander, A., Groben, P. A., Parrish, E., Kricker, A., Armstrong, B. K., Anton-Culver, H., Gruber, S. B., From, L., et al. (2015) · JAMA Oncology · doi:10.1001/jamaoncol.2015.0493 · Cited by 196
Multibatch TMT reveals false positives, batch effects and missing values
Brenes, A., Hukelmann, J., Bensaddek, D., & Lamond, A. I. (2019) · Molecular & Cellular Proteomics · doi:10.1074/mcp.ra119.001472 · Cited by 196
The Role of Toll-Like Receptor in Inflammation and Tumor Immunity
Cen, X., Liu, S., & Cheng, K. (2018) · Frontiers in Pharmacology · doi:10.3389/fphar.2018.00878 · Cited by 188
The World of Melanoma: Epidemiologic, Genetic, and Anatomic Differences of Melanoma Across the Globe
Dimitriou, F., Krattinger, R., Ramelyte, E., Barysch, M. J., Micaletto, S., Dummer, R., & Goldinger, S. M. (2018) · Current Oncology Reports · doi:10.1007/s11912-018-0732-8 · Cited by 179
Tumor Neovascularization and Developments in Therapeutics
Katayama, Y., Uchino, J., Chihara, Y., Tamiya, N., Kaneko, Y., Yamada, T., & Takayama, K. (2019) · Cancers · doi:10.3390/cancers11030316 · Cited by 161
Detection of BRAF p.V600E Mutations in Melanomas
Colomba, E., Hélias-Rodzewicz, Z., Von Deimling, A., Marin, C., Terrones, N., Pechaud, D., Surel, S., Côté, J.-F., Peschaud, F., Capper, D., et al. (2013) · The Journal of Molecular Diagnostics · doi:10.1016/j.jmoldx.2012.09.001 · Cited by 160
NF 1‐mutated melanoma tumors harbor distinct clinical and biological characteristics
Cirenajwis, H., Lauss, M., Ekedahl, H., Törngren, T., Kvist, A., Saal, L. H., Olsson, H. L., Staaf, J., Carneiro, A., Ingvar, C., et al. (2017) · Molecular Oncology · doi:10.1002/1878-0261.12050 · Cited by 156
Self-citationThe clinical significance ofBRAFandNRASmutations in a clinic-based metastatic melanoma cohort
Ekedahl, H., Cirenajwis, H., Harbst, K., Carneiro, A., Nielsen, K., Olsson, H. L., Lundgren, L., Ingvar, C., & Jonsson, G. G. (2013) · British Journal of Dermatology · doi:10.1111/bjd.12504 · Cited by 125
Self-citationLin, J., Goto, Y., Murata, H., Sakaizawa, K., Uchiyama, A., Saida, T., & Takata, M. (2011) · British Journal of Cancer · doi:10.1038/sj.bjc.6606072 · Cited by 124
Carlino, M. S., Haydu, L. E., Kakavand, H., Menzies, A. M., Hamilton, A. L., Yu, B., Ng, C. C., Cooper, W. A., Thompson, J. F., Kefford, R. F., et al. (2014) · British Journal of Cancer · doi:10.1038/bjc.2014.287 · Cited by 108
Lin, X., Sun, R., Zhao, X., Zhu, D., Zhao, X., Gu, Q., Dong, X., Zhang, D., Zhang, Y., Li, Y., et al. (2016) · Journal of Molecular Medicine · doi:10.1007/s00109-016-1452-x · Cited by 105
HDGF: A Novel Jack-of-All-Trades in Cancer
Bao, C., Wang, J., Ma, W., Wang, X., & Cheng, Y. (2014) · Future Oncology · doi:10.2217/fon.14.194 · Cited by 81
Barbour, A. P., Tang, Y., Armour, N., Dutton‐Regester, K., Krause, L., Loffler, K. A., Lambie, D., Burmeister, B. H., Thomas, J. M., Smithers, B. M., et al. (2014) · European Journal of Cancer · doi:10.1016/j.ejca.2014.06.009 · Cited by 76
Hugdahl, E., Kalvenes, M. B., Puntervoll, H. E., Ladstein, R. G., & Akslen, L. A. (2016) · British Journal of Cancer · doi:10.1038/bjc.2016.44 · Cited by 75 · cited 2×
“In comparison to DNA-based assays, these studies have shown a high sensitivity and specificity in detecting BRAF mutants, with a study reporting B-raf V600E protein expression as a novel prognostic marker in primary melanoma [25].”
ResultIn vitro evidence for senescent multinucleated melanocytes as a source for tumor-initiating cells
Leikam, C., Hufnagel, A. L., Otto, C., Murphy, D. J., Mühling, B., Kneitz, S., Nanda, I., Schmid, M., Wagner, T. U., Haferkamp, S., et al. (2015) · Cell Death & Disease · doi:10.1038/cddis.2015.71 · Cited by 74
Litwiniec, A., Gackowska, L., Helmin–Basa, A., Żuryń, A., & Grzanka, A. (2013) · Cancer Cell International · doi:10.1186/1475-2867-13-9 · Cited by 64
López‐Ríos, F., Angulo, B., Gomez, B., Mair, D., Martínez, R., Conde, E., Shieh, F., Vaks, J. E., Langland, R., Lawrence, H. J., et al. (2013) · PLoS ONE · doi:10.1371/journal.pone.0053733 · Cited by 64
Validation of the VE1 immunostain for the BRAF V600E mutation in melanoma
Pearlstein, M. V., Zedek, D. C., Ollila, D. W., Treece, A. L., Gulley, M. L., Groben, P. A., & Thomas, N. E. (2014) · Journal of Cutaneous Pathology · doi:10.1111/cup.12364 · Cited by 61
Survival According to BRAF-V600 Tumor Mutations – An Analysis of 437 Patients with Primary Melanoma
Meckbach, D., Bauer, J. M., Pflugfelder, A., Meier, F. E., Busch, C., Eigentler, T., Capper, D., von Deimling, A., Mittelbronn, M. G. A., Perner, S., et al. (2014) · PLoS ONE · doi:10.1371/journal.pone.0086194 · Cited by 55
Clinical protein science in translational medicine targeting malignant melanoma
Gil, J., Betancourt, L. H., Pla, I., Sanchez, A., Appelqvist, R., Miliotis, T., Kuras, M., Oskolas, H., Kim, Y., Horvath, Z., et al. (2019) · Cell Biology and Toxicology · doi:10.1007/s10565-019-09468-6 · Cited by 45
Self-citationSpathis, A., Katoulis, A., Damaskou, V., Liakou, A. Ι., Kottaridi, C., Leventakou, D., Sgouros, D., Mamantopoulos, A., Rigopoulos, D., Karakitsos, P., et al. (2019) · Dermatology Practical & Conceptual · doi:10.5826/dpc.0901a13 · Cited by 39
(MUS), M. U. O. S., Manca, A., (IMI), F. T. I. M. I., Paliogiannis, P., Colombino, M., Casula, M., Lissia, A., Botti, G., Caracò, C., Ascierto, P. A., et al. (2019) · Journal of Translational Medicine · doi:10.1186/s12967-019-2039-4 · Cited by 38
Manfredi, L., Meyer, N., Tournier, É., Grand, D., Uro‐Coste, E., Rochaix, P., Brousset, P., & Lamant, L. (2015) · Acta Dermato Venereologica · doi:10.2340/00015555-2326 · Cited by 36
Welinder, C., Pawłowski, K., Szász, A. M., Yakovleva, M., Sugihara, Y., Malm, J., Jönsson, G. B., Ingvar, C., Lundgren, L., Baldetorp, B., et al. (2017) · PLoS ONE · doi:10.1371/journal.pone.0176167 · Cited by 35
Self-citationSchirosi, L., Strippoli, S., Gaudio, F. D., Graziano, G., Popescu, O., Guida, M., Simone, G., & Mangia, A. (2016) · BMC Cancer · doi:10.1186/s12885-016-2951-4 · Cited by 35
BRAFV600EProtein Expression in Primary Cutaneous Malignant Melanomas and Paired Metastases
Eriksson, H., Zebary, A., Vassilaki, I., Omholt, K., Ghaderi, M., & Hansson, J. (2015) · JAMA Dermatology · doi:10.1001/jamadermatol.2014.3689 · Cited by 32
Kuras, M., Betancourt, L. H., Rezeli, M., Murillo, J. R., Szász, A. M., Zhou, Q., Miliotis, T., Andersson, R. E., & Marko‐Varga, G. (2018) · Journal of Proteome Research · doi:10.1021/acs.jproteome.8b00792 · Cited by 29
Self-citationMelanoma genotypes and phenotypes get personal
Pimiento, J. M., Larkin, E. M., Smalley, K. S. M., Wiersma, G., Monks, N. R., Smalley, I., Peterson, C. A., & Nickoloff, B. J. (2013) · Laboratory Investigation · doi:10.1038/labinvest.2013.84 · Cited by 26
Mitotic rate is associated with positive lymph nodes in patients with thin melanomas
Wheless, L., Isom, C. A., Hooks, M. A., & Kauffmann, R. M. (2017) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2017.11.041 · Cited by 26
Doma, V., Kárpáti, S., Rásó, E., Barbai, T., & Tímár, J. (2019) · BMC Cancer · doi:10.1186/s12885-019-5990-9 · Cited by 25
Proteomics for cancer drug design
Haymond, A. N., Davis, J. B., & Espina, V. A. (2019) · Expert Review of Proteomics · doi:10.1080/14789450.2019.1650025 · Cited by 24
Szász, A. M., Malm, J., Rezeli, M., Sugihara, Y., Betancourt, L. H., Rivas, D., Győrffy, B., & Marko‐Varga, G. (2018) · Cell Biology and Toxicology · doi:10.1007/s10565-018-9446-9 · Cited by 24
Self-citationClinical and therapeutic implications of BRAF mutation heterogeneity in metastatic melanoma
Ardakani, N. M., Leslie, C., Grieu‐Iacopetta, F., Lam, W., Budgeon, C. A., Millward, M. J., & Amanuel, B. (2016) · Pigment Cell & Melanoma Research · doi:10.1111/pcmr.12569 · Cited by 21
Kulka, J., Székely, B., Lukács, L., Kiss, O., Tőkés, A.-M., Vincze, E., Turányi, E., Fillinger, J., Hanzély, Z., Arató, G., et al. (2016) · Journal of Histochemistry & Cytochemistry · doi:10.1369/0022155416639013 · Cited by 20
Plym, A., Ullenhag, G. J., Breivald, M., Lambe, M. P., & Berglund, A. (2013) · Acta Oncologica · doi:10.3109/0284186x.2013.854928 · Cited by 20
Utilization of Proteomic Technologies for Precision Oncology Applications
Pierobon, M., Wulfkuhle, J., Liotta, L. A., & Petricoin, E. F. (2019) · Cancer treatment and research · doi:10.1007/978-3-030-16391-4_6 · Cited by 17
Betancourt, L. H., Pawłowski, K., Eriksson, J. O., Szász, A. M., Mitra, S., Plá, I., Welinder, C., Ekedahl, H., Broberg, P., Appelqvist, R., et al. (2019) · Scientific Reports · doi:10.1038/s41598-019-41625-z · Cited by 15
Self-citationArmstrong, B. K., Luo, L., Marrett, L. D., Groben, P. A., Orlow, I., From, L., Dwyer, T., Parrish, E., Thomas, N. E., Bramson, J. I., et al. (2020) · Carolina Digital Repository (University of North Carolina at Chapel Hill) · doi:10.17615/w89f-qy51 · Cited by 15
Ilmonen, S., Asko-Seljavaara, S. L., Al, K., Jeskanen, L., Pyrhönen, S. O., & Muhonen, T. T. (2002) · Scandinavian Journal of Surgery · doi:10.1177/145749690209100206 · Cited by 14
Rapisuwon, S., BUSAM, K. J., Parks, K., Chapman, P. B., Lee, E., & Atkins, M. B. (2016) · American Journal of Dermatopathology · doi:10.1097/dad.0000000000000660 · Cited by 12
Chen, H., Hsiao, Y.-C., Chiang, S.-F., Wu, C., Lin, Y.-T., Liu, H., Zhao, H., Chen, J., Chang, Y., & Yu, J. (2016) · Analytica Chimica Acta · doi:10.1016/j.aca.2016.05.037 · Cited by 9
Cancer therapeutics through an evolutionary lens
Swanton, C. (2018) · Journal of the Royal Society of Medicine · doi:10.1177/0141076817742096 · Cited by 8
Kulka, J., Székely, B., Lukács, L., Kiss, O., Tokes, A.-M., Vincze, E., Turányi, E., Fillinger, J., Hanzély, Z., Arato, G., et al. (2016) · Repository of the Academy's Library (Library of the Hungarian Academy of Sciences) · Cited by 5
Self-citation
Research works printed but not linked: 1
- Balch, 2001, Prognostic Factors Analysis of 17, 600 Melanoma Patients: Melanoma Staging System, Society, 19, 3622
Cited by
A high-stringency blueprint of the human proteome
Adhikari, S., Nice, E. C., Deutsch, E. W., Lane, L., Omenn, G. S., Pennington, S. R., Paik, Y.-K., Overall, C. M., Corrales, F. J., Cristea, I. M., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-19045-9 · Cited by 210
Self-citationThe Role of Toll-Like Receptor in Inflammation and Tumor Immunity
Cen, X., Liu, S., & Cheng, K. (2018) · Frontiers in Pharmacology · doi:10.3389/fphar.2018.00878 · Cited by 188
Melanoma Management: From Epidemiology to Treatment and Latest Advances
Lopes, J., Rodrigues, C. M. P., Gaspar, M. M., & Reis, C. P. (2022) · Cancers · doi:10.3390/cancers14194652 · Cited by 182
BRAF Heterogeneity in Melanoma
Ito, T., Tanaka, Y., Murata, M., Kaku‐Ito, Y., Furue, K., & Furue, M. (2021) · Current Treatment Options in Oncology · doi:10.1007/s11864-021-00818-3 · Cited by 49
Clinical protein science in translational medicine targeting malignant melanoma
Gil, J., Betancourt, L. H., Pla, I., Sanchez, A., Appelqvist, R., Miliotis, T., Kuras, M., Oskolas, H., Kim, Y., Horvath, Z., et al. (2019) · Cell Biology and Toxicology · doi:10.1007/s10565-019-09468-6 · Cited by 45
Self-citation
Metadata
- Authors
- Betancourt, L. H., Szasz, A. M., Kuras, M., Rodriguez Murillo, J., Sugihara, Y., Pla, I., Horvath, Z., Pawłowski, K., Rezeli, M., Miharada, K., Gil, J., Eriksson, J., Appelqvist, R., Miliotis, T., Baldetorp, B., Ingvar, C., Olsson, H., Lundgren, L., Horvatovich, P., Welinder, C., Wieslander, E., Kwon, H. J., Malm, J., Nemeth, I. B., Jönsson, G., Fenyö, D., Sanchez, A., & Marko-Varga, G.
- Affiliations
- Lund University (SE)
- Clinical Protein Science & Imaging, Biomedical Centre, Department of Biomedical, Engineering, Lund University, BMC D13, 221 84 Lund, Sweden
- Division of Physiological Chemistry I, Department of Medical Biochemistry and Biophysics, Karolinska Institutet, SE-17 177 Stockholm, Sweden
- Section for Clinical Chemistry, Department of Translational Medicine, Lund University, Skåne University Hospital Malmö, 205 02 Malmö, Sweden
- Warsaw University of Life Sciences (PL)
- AstraZeneca (Sweden) (SE)
- Division of Oncology and Pathology, Department of Clinical Sciences Lund, Lund University, 221 85 Lund, Sweden
- University of Groningen (NL)
- Yonsei University (KR)
- Department of Dermatology and Allergology, University of Szeged, H-6720 Szeged, Hungary
- NYU Langone Health (US)
- ORCID
- Betancourt, Lazaro Hiram
- Szasz, A. Marcell
- Kuras, Magdalena
- Sugihara, Yutaka
- Pla, Indira
- Pawłowski, Krzysztof
- Rezeli, Melinda
- Miharada, Kenichi
- Gil, Jeovanis
- Eriksson, Jonatan
- Appelqvist, Roger
- Miliotis, Tasso
- Ingvar, Christian
- Horvatovich, Peter
- Welinder, Charlotte
- Kwon, Ho Jeong
- Malm, Johan
- Fenyö, David
- Sanchez, Aniel
- Venue
- Cancers
- Publisher
- MDPI AG
- Published
- 2019-12-09
- Volume
- 11
- Issue
- 12
- Pages
- 1981
- ISSN
- 2072-6694 (ISSN-L)
- PMC
- PMC6966659
- OpenAlex
- W2982318968
- Cited by
- 24
- References
- 64
- Citations by year
- 2025: 2 · 2023: 3 · 2022: 2 · 2021: 7 · 2020: 6 · 2019: 3
- FWCI
- 1.49
- Type
- journal article
- Language
- en
- Open access
- gold
- dx.doi.org
- Licence
- Locations
- Cancers (publishedVersion, cc-by)
- Preprints.org (acceptedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- University of Groningen research database (University of Groningen / Centre for Information Technology) (publishedVersion, cc-by)
- Lund University Publications (Lund University) (submittedVersion)
- University of Groningen research database (University of Groningen / Centre for Information Technology) (submittedVersion, cc-by)
- Funders
- Nemzeti Kutatási, Fejlesztési és Innovaciós Alap (KNN121510)
- Berta Kamprad Foundation (01)
- ThermoFisher Scientific (01)
- Liconic Biobanking (01)
- Global (01)
- National Research Foundation of Korea (2015K1A1A2028365 and 2016K2A9A1A03904900)
- Korean Government (2016K2A9A1A03904900)
- Brain Korea 21 (01)
- Republic of Korea (01)
- NIH/NCI International Cancer Proteogenome Consortium (01)
- The Mats Paulsson Trust (01)
- The Stefan Paulsson Trust (01)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Melanoma and MAPK Pathways
- Health Sciences › Medicine › Oncology › Cutaneous Melanoma Detection and Management
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
- Keywords
- metastatic melanoma, BRAF V600E mutation, protein quantification, intratumoral heterogeneity, intertumoral heterogeneity, tumor phenotype, clinical outcomes, targeted therapy, drug response prediction, tumor progression
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.